Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This will be a single center, prospective, open-label, randomized, controlled trial comparing
Envarsus XR® to twice-daily tacrolimus. The targeted population will be patients with end
stage renal disease listed for primary solitary kidney transplant. Transplant Surgery is not
part of the study.